Details of the Drug

General Information of Drug (ID: DMTSGOW)

Drug Name
[3H]methyltrienolone
Synonyms
Methyltrienolone; METRIBOLONE; 965-93-5; R1881; Metribolona; 17alpha-Methyltrienolone; Metribolonum; RU 1881; Ru-1881; R 1881; UNII-2C323EGI97; 17beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; 17-beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; R-1881; R1881 (synthetic androgen); CHEBI:379896; 2C323EGI97; (17BETA)-17-HYDROXY-17-METHYLESTRA-4,9,11-TRIEN-3-ONE; 17-methyloestra-4,9,11-trien-3-one,17beta-ol; 17-beta-hydroxy-17-methylestra-4,9,11-trien-3-one (9CI); Estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17b)-; [3H]-R1881; [3H]R1881
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 284.4
Logarithm of the Partition Coefficient (xlogp) 2.1
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C19H24O2
IUPAC Name
(8S,13S,14S,17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES
C[C@@]1(CC[C@@H]2[C@@]1(C=CC3=C4CCC(=O)C=C4CC[C@@H]23)C)O
InChI
InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1
InChIKey
CCCIJQPRIXGQOE-XWSJACJDSA-N
Cross-matching ID
PubChem CID
261000
ChEBI ID
CHEMBL166444
CAS Number
965-93-5
UNII
2C323EGI97
DrugBank ID
DB02998
TTD ID
D01ETZ
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Inhibitor [2]
Androgen receptor messenger RNA (AR mRNA) TTKPW01 ANDR_HUMAN Agonist [3]
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
2-oxoglutarate dehydrogenase complex component E1 (OGDH) OTHGTQWF ODO1_HUMAN Gene/Protein Processing [4]
26S proteasome non-ATPase regulatory subunit 2 (PSMD2) OT6HZHN7 PSMD2_HUMAN Gene/Protein Processing [5]
26S proteasome non-ATPase regulatory subunit 6 (PSMD6) OTX59EGK PSMD6_HUMAN Gene/Protein Processing [4]
26S proteasome regulatory subunit 4 (PSMC1) OTLHD56E PRS4_HUMAN Gene/Protein Processing [5]
26S proteasome regulatory subunit 6A (PSMC3) OTSKT0JI PRS6A_HUMAN Gene/Protein Processing [5]
3-hydroxyisobutyrate dehydrogenase, mitochondrial (HIBADH) OTCMMMIZ 3HIDH_HUMAN Gene/Protein Processing [5]
4'-phosphopantetheine phosphatase (PANK4) OTMLNEPU PANK4_HUMAN Gene/Protein Processing [5]
4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1) OTNWHUJ1 AL9A1_HUMAN Gene/Protein Processing [5]
5'-3' exoribonuclease 1 OTBBT1D8 XRN1_HUMAN Gene/Protein Processing [6]
A-kinase-interacting protein 1 (AKIP1) OT7XPG27 AKIP1_HUMAN Gene/Protein Processing [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Androgen receptor (AR) DTT AR 2.13E-01 -0.07 -0.11
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3457).
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
4 Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics. 2006 Sep 29;7:246. doi: 10.1186/1471-2164-7-246.
5 Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics. 2007 Jan;7(1):47-63.
6 A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. Oncotarget. 2015 Apr 10;6(10):7686-700. doi: 10.18632/oncotarget.3480.